Related Experiment Video
Updated: Feb 18, 2026
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future
Rafael Alvim Pereira1, Christian Oliveira2, Milena Tumelero3
1Department of Medicine, Hospital Santa Casa, São José dos Campos, Brazil, raralvim5@gmail.com.
Background:
KRAS mutations, particularly G12C, frequently cause non-small cell lung cancer (NSCLC). Due to the protective nature of the blood-brain barrier and the paucity of clinical data specifically about CNS involvement, brain metastases - which occur in up to 40% of patients with advanced KRAS-mutant NSCLC - present unique therapeutic challenges.
Summary:
The changing role of KRAS-targeted treatments in NSCLC with metastases to the central nervous system (CNS) is examined in this review. It highlights new clinical findings on KRAS G12C inhibitors, including sotorasib and adagrasib, and discusses the challenges in delivering medications across the blood-brain barrier. Along with outlining important resistance mechanisms, such as bypass signaling pathways, secondary KRAS mutations, and SHP2-mediated feedback, the review also examines new combination strategies that utilize SHP2 inhibitors, immunotherapy, and radiation.
Key Messages:
Even with recent progress in treatment, brain metastases continue to pose a significant challenge in managing KRAS-mutant NSCLC. Among currently available agents, adagrasib has shown encouraging intracranial activity and CNS penetration, and rational combination strategies are being explored to overcome resistance. Ongoing research should prioritize CNS-specific endpoints and integrated treatment approaches tailored to patients with brain involvement.
Insights
KRAS G12C inhibitors show promise for non-small cell lung cancer (NSCLC) brain metastases, but challenges remain. New strategies combining KRAS inhibitors with other therapies are being explored to improve outcomes for patients with central nervous system (CNS) involvement.
Area of Science:
- Oncology
- Pharmacology
- Neuro-oncology
Background:
- KRAS mutations, especially G12C, are common drivers in non-small cell lung cancer (NSCLC).
- Brain metastases occur in up to 40% of advanced KRAS-mutant NSCLC patients, posing significant therapeutic challenges due to the blood-brain barrier.
- Limited clinical data exists specifically addressing central nervous system (CNS) involvement in these patients.
Purpose of the Study:
- To review the evolving role of KRAS-targeted therapies in NSCLC with CNS metastases.
- To highlight recent clinical findings on KRAS G12C inhibitors like sotorasib and adagrasib.
- To discuss challenges in achieving adequate drug penetration across the blood-brain barrier.
Main Methods:
- Review of current clinical findings and literature on KRAS G12C inhibitors.
- Analysis of resistance mechanisms to targeted therapies.
- Exploration of novel combination strategies.
Main Results:
- Adagrasib demonstrates promising intracranial activity and CNS penetration.
- Key resistance mechanisms include bypass signaling, secondary KRAS mutations, and SHP2 feedback.
- Combination strategies involving SHP2 inhibitors, immunotherapy, and radiation are under investigation.
Conclusions:
- Brain metastases remain a significant challenge in KRAS-mutant NSCLC management despite treatment advancements.
- Adagrasib shows potential for CNS-targeted therapy in NSCLC brain metastases.
- Further research focusing on CNS-specific endpoints and integrated treatment approaches is crucial for patients with brain involvement.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists